Dendritic cells in tolerance induction for the treatment of autoimmune diseases

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.

Original languageEnglish
Pages (from-to)2119-2123
Number of pages5
JournalEuropean Journal of Immunology
Volume40
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Dendritic Cells
Autoimmune Diseases
Antigens
Immunomodulation
Autoantigens
Immunosuppressive Agents
Therapeutics
Pharmaceutical Preparations

Keywords

  • CD103
  • DC
  • TGF-β
  • Tolerance
  • TSLP

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Dendritic cells in tolerance induction for the treatment of autoimmune diseases. / Rescigno, Maria.

In: European Journal of Immunology, Vol. 40, No. 8, 08.2010, p. 2119-2123.

Research output: Contribution to journalArticle

@article{99d63c98cc6748589dcd5db2e75ce9d4,
title = "Dendritic cells in tolerance induction for the treatment of autoimmune diseases",
abstract = "Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.",
keywords = "CD103, DC, TGF-β, Tolerance, TSLP",
author = "Maria Rescigno",
year = "2010",
month = "8",
doi = "10.1002/eji.201040474",
language = "English",
volume = "40",
pages = "2119--2123",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "8",

}

TY - JOUR

T1 - Dendritic cells in tolerance induction for the treatment of autoimmune diseases

AU - Rescigno, Maria

PY - 2010/8

Y1 - 2010/8

N2 - Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.

AB - Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.

KW - CD103

KW - DC

KW - TGF-β

KW - Tolerance

KW - TSLP

UR - http://www.scopus.com/inward/record.url?scp=77956132493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956132493&partnerID=8YFLogxK

U2 - 10.1002/eji.201040474

DO - 10.1002/eji.201040474

M3 - Article

VL - 40

SP - 2119

EP - 2123

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 8

ER -